SARC020

May 5, 2021

Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma

TYPE OF SARCOMA: Advanced or Metastatic Untreated Soft Tissue Sarcoma
DRUG: Trabectedin Infused to Doxorubicin

ACCRUAL STATUS: Terminated

OVERALL STUDY PRINCIPAL INVESTIGATOR:
James E. Butrynski, MD
Dana-Farber Cancer Institute

CLINICALTRIALS.GOV IDENTIFIER: NCT01189253

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

To learn more about this study or to contact the study research staff:

contact sarc

Back to top